EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials

R Taylor Sundby iD, Steven D Rhodes, Edina Komlodi-Pasztor, Herb Sarnoff, Vito Grasso, Meena Upadhyaya, AeRang Kim, D Gareth Evans, Jaishri O Blakeley, C Oliver Hanemann, Chetan Bettegowda

Clinical Trials · 2024

DOI: 10.1177/17407745231203330 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Trials, 2024. Verfasst von R Taylor Sundby und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibromatosis 2, Neurofibromatoses, Neurilemmoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NINDS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neurofibromatosis 1 and schwannomatosis are characterized by potential lifelong morbidity and life-threatening complications. To date, however, diagnostic and predictive biomarkers are an unmet need in this patient population. The inclusion of biomarker discovery correlatives in neurofibromatosis 1/schwannomatosis clinical trials enables study of low-incidence disease. The implementation of a common data model would further enhance biomarker discovery by enabling effective concatenation of data from multiple studies.

Methods

The Response Evaluation in Neurofibromatosis and Schwannomatosis biomarker working group reviewed published data on emerging trends in neurofibromatosis 1 and schwannomatosis biomarker research and developed recommendations in a series of consensus meetings.

Results

Liquid biopsy has emerged as a promising assay for neurofibromatosis 1/schwannomatosis biomarker discovery and validation. In addition, we review recommendations for a range of biomarkers in clinical trials, neurofibromatosis 1/schwannomatosis–specific data annotations, and common data models for data integration.

Conclusion

These Response Evaluation in Neurofibromatosis and Schwannomatosis consensus guidelines are intended to provide best practices for the inclusion of biomarker studies in neurofibromatosis 1/schwannomatosis clinical trials, data, and sample annotation and to lay a framework for data harmonization and concatenation between trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1Neurofibromatosis 2NeurofibromatosesNeurilemmomaSkin NeoplasmsHumansBiomarkers

Stichwörter der Autor:innen

Biomarkercell-free DNAconsensus guidelinescytokinesliquid biopsyneurofibromatosisopen scienceschwannomatosis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
  • Division of Hematology/Oncology/Stem Cell Transplant, Department of Pediatrics, Herman B Wells Center for Pediatric Research, School of Medicine, Indiana University, Indianapolis, IN, USA.
  • Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Research and Development, Infixion Bioscience, Inc., San Diego, CA, USA.
  • Patient Representative, REiNS International Collaboration, San Diego, CA, USA.
  • Neural Stem Cell Institute, Rensselaer, NY, USA.

ORCID-Profile: R Taylor Sundby

Förderung

  • NIH HHS
  • NINDS NIH HHS
  • NCI NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Sundby, R. T., Rhodes, S. D., Komlodi-Pasztor, E., Sarnoff, H., Grasso, V., Upadhyaya, M., Kim, A., Evans, D. G., Blakeley, J. O., Hanemann, C. O., & Bettegowda, C. (2024). Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials. Clinical Trials. https://doi.org/10.1177/17407745231203330

Vancouver

Sundby RT, Rhodes SD, Komlodi-Pasztor E, Sarnoff H, Grasso V, Upadhyaya M, et al. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials. Clinical Trials. 2024. doi:10.1177/17407745231203330

BibTeX
@article{Sundby2024,
  author = {Sundby, R Taylor and Rhodes, Steven D and Komlodi-Pasztor, Edina and Sarnoff, Herb and Grasso, Vito and Upadhyaya, Meena and Kim, AeRang and Evans, D Gareth and Blakeley, Jaishri O and Hanemann, C Oliver and Bettegowda, Chetan},
  title = {Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials},
  journal = {Clinical Trials},
  year = {2024},
  doi = {10.1177/17407745231203330}
}
Kostenlos starten →